Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolajs Zeps

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52Mona Shehata, Ivan Bièche, Rose Boutros, et al.
Stem Cell Reports|July 2, 2021
Ethics and regulatory considerations for the clinical translation of somatic cell human epigenetic editingNikolajs Zeps, Tamra Lysaght, Ruth Chadwick, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|March 18, 2009
Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sectionsMaryla Krajewska, Layton H Smith, Juan Rong, et al.
Carcinogenesis|December 5, 2013
CHIP/Stub1 functions as a tumor suppressor and represses NF-κB-mediated signaling in colorectal cancerYangmeng Wang, Fangli Ren, Yinyin Wang, et al.
Nature Biotechnology|June 10, 2014
The International Cancer Genome Consortium's evolving data-protection policiesDjims Milius, Edward S Dove, Donald Chalmers, et al.
Trials|September 16, 2021
Normalising comparative effectiveness trials as clinical practiceTom Briffa, Tanya Symons, Nikolajs Zeps, et al.
Biomarker Insights|February 17, 2022
Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to SustainabilityCarmel M Quinn, Mamta Porwal, Nicola S Meagher, et al.
Oncoimmunology|September 14, 2016
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancerRosemary Millen, Jordane Malaterre, Ryan S Cross, et al.
Oncotarget|February 9, 2017
Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment responseMelanie J McCoy, Chris Hemmings, Chidozie C Anyaegbu, et al.
The American Journal of Pathology|February 22, 2012
Villin expression is frequently lost in poorly differentiated colon cancerDiego Arango, Sheren Al-Obaidi, David S Williams, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52Mona Shehata, Ivan Bièche, Rose Boutros, et al.
Stem Cell Reports|July 2, 2021
Ethics and regulatory considerations for the clinical translation of somatic cell human epigenetic editingNikolajs Zeps, Tamra Lysaght, Ruth Chadwick, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|March 18, 2009
Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sectionsMaryla Krajewska, Layton H Smith, Juan Rong, et al.
Carcinogenesis|December 5, 2013
CHIP/Stub1 functions as a tumor suppressor and represses NF-κB-mediated signaling in colorectal cancerYangmeng Wang, Fangli Ren, Yinyin Wang, et al.
Nature Biotechnology|June 10, 2014
The International Cancer Genome Consortium's evolving data-protection policiesDjims Milius, Edward S Dove, Donald Chalmers, et al.
Trials|September 16, 2021
Normalising comparative effectiveness trials as clinical practiceTom Briffa, Tanya Symons, Nikolajs Zeps, et al.
Biomarker Insights|February 17, 2022
Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to SustainabilityCarmel M Quinn, Mamta Porwal, Nicola S Meagher, et al.
Oncoimmunology|September 14, 2016
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancerRosemary Millen, Jordane Malaterre, Ryan S Cross, et al.
Oncotarget|February 9, 2017
Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment responseMelanie J McCoy, Chris Hemmings, Chidozie C Anyaegbu, et al.
The American Journal of Pathology|February 22, 2012
Villin expression is frequently lost in poorly differentiated colon cancerDiego Arango, Sheren Al-Obaidi, David S Williams, et al.
Pageof 6